Search Result

Results for "

rat cortex

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (8) Adrenergic Receptor (10) Amino Acid Derivatives (1) Amyloid-β (1) Apoptosis (3) Calcium Channel (2) Cholecystokinin Receptor (2) Cholinesterase (ChE) (3) Dopamine Receptor (1) Dopamine Transporter (2) Endogenous Metabolite (3) GABA Receptor (2) GlyT (1) GSK-3 (1) HDAC (1) Histamine Receptor (3) Histone Methyltransferase (1) iGluR (3) JNK (1) mAChR (1) mGluR (1) Monoamine Transporter (1) nAChR (1) Neurokinin Receptor (3) NO Synthase (2) Opioid Receptor (1) Phosphatase (2) Reactive Oxygen Species (2) SARS-CoV (2) Somatostatin Receptor (1) Trk Receptor (1) α-synuclein (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Endocrinology (2) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (37)

By Targets:

5-HT Receptor (8)

Adrenergic Receptor (10)

Amino Acid Derivatives (1)

Amyloid-β (1)

Apoptosis (3)

Calcium Channel (2)

Cholecystokinin Receptor (2)

Cholinesterase (ChE) (3)

Dopamine Receptor (1)

Dopamine Transporter (2)

Endogenous Metabolite (3)

GABA Receptor (2)

GlyT (1)

GSK-3 (1)

HDAC (1)

Histamine Receptor (3)

Histone Methyltransferase (1)

iGluR (3)

JNK (1)

mAChR (1)

mGluR (1)

Monoamine Transporter (1)

nAChR (1)

Neurokinin Receptor (3)

NO Synthase (2)

Opioid Receptor (1)

Phosphatase (2)

Reactive Oxygen Species (2)

SARS-CoV (2)

Somatostatin Receptor (1)

Trk Receptor (1)

α-synuclein (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (3)

Endocrinology (2)

Inflammation/Immunology (9)

Metabolic Disease (3)

Neurological Disease (37)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101333

CPPG (RS)-CPPG	mGluR	Neurological Disease
CPPG ((RS)-CPPG) is a potent group II/III mGlu receptors antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC₅₀=2.2 nM) over group II (IC₅₀=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-103509

NNC 05-2090 hydrochloride	GABA Receptor	Neurological Disease
NNC 05-2090 hydrochloride is a GABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC_{50< /sub>}: 10.6 μM). NNC 05-2090 hydrochloride also inhibits mGAT2 with a K_i value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .

HY-121186

Bevantolol hydrochloride	Adrenergic Receptor Calcium Channel	Cardiovascular Disease Neurological Disease Metabolic Disease
Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

HY-107563

ROS 234	Histamine Receptor	Inflammation/Immunology
ROS 234 is a potent H3 antagonist, with a pK_B of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 diaplays poor central access .

HY-107563A

ROS 234 dioxalate	Histamine Receptor	Inflammation/Immunology
ROS 234 dioxalate is a potent H3 antagonist, with a pK_B of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 dioxalate diaplays poor central access .

HY-106874B

rel-Delequamine rel-RS-15385-197	Adrenergic Receptor	Neurological Disease
rel-Delequamine (rel-RS-15385-197) is an orally active, brain-penetrant, potent and selective M₂-adrenoceptor antagonist and α₂-adrenoceptor antagonist. rel-Delequamine has a pK_i of 9.45 for α₂-adrenoceptors in the rat cortex. rel-Delequamine augments K ⁺-evoked release of noradrenaline with an EC₅₀ of 1 nM .

HY-P1588

Scyliorhinin II	Neurokinin Receptor	Neurological Disease Endocrinology
Scyliorhinin II is a selective neurokinin-3 receptor agonist, with a K_i of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.

HY-W203728

L-β-Imidazolelactic acid	Amino Acid Derivatives	Neurological Disease
L-β-Imidazolelactic acid is a histidine derivative and an oxidizing agent that can trigger antioxidant effects in the brain cortex of rats .

HY-107562

JNJ 10181457 dihydrochloride	Histamine Receptor	Neurological Disease
JNJ-10181457 is a neutral, potent, brain-penetrant and selective non-imidazole H₃ antagonist which increases NE and ACh concentrations in rat frontal cortex. JNJ-10181457 can be used for neurological research .

HY-12959A

Repinotan hydrochloride BAY x 3702	5-HT Receptor	Neurological Disease
Repinotan hydrochloride (BAY x 3702) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus Repinotan hydrochloride has a weak affinity for other related receptors. Repinotan hydrochloride has pronounced neuroprotective effects .

HY-12959

Repinotan BAY x 3702 free base	5-HT Receptor	Neurological Disease
Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus). Repinotan has a weak affinity for other related receptors. Repinotan has pronounced neuroprotective effects .

HY-160932

RS-15385-198	Adrenergic Receptor	Endocrinology
RS-15385-198 is the enantiomer of Delequamine (RS-15385-197) (HY-106874). RS-15385-198 exhibits a pK_i of 6.32 for α₂-adrenoceptors in the rat cortex. RS-15385-198 is an antagonist for UK-14304 (HY-B0659) in the rat vas deferens and in the guinea-pig ileum .

HY-100481

RP 72540 RPR101048	Cholecystokinin Receptor	Neurological Disease
RP 72540 is a selective CCK-B receptor antagonist, with IC₅₀ values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .

HY-126862

AQ-RA 721	mAChR	Others
AQ-RA 721 is a muscarinic receptor antagonist with differential affinity for the m4 and M2 sites, which can be used to characterize muscarinic receptor subtypes. Other muscarinic receptor antagonists have differential affinity for the M1 (rat cerebral cortex), M2 (rat heart), M3 (rat submandibular gland), m4 (receptor expressed in Chinese hamster ovary cells transfected with CHO), and guinea pig uterine smooth muscle at the muscarinic binding site .

HY-119409

Levophacetoperane Phacetoperane free base	Dopamine Transporter	Neurological Disease
Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine .

HY-121186R

Bevantolol (hydrochloride) (Standard)	Adrenergic Receptor Calcium Channel	Neurological Disease Metabolic Disease
Bevantolol (hydrochloride) (Standard) is the analytical standard of Bevantolol (hydrochloride). This product is intended for research and analytical applications. Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

HY-113149

Argininosuccinic acid	Endogenous Metabolite Reactive Oxygen Species	Inflammation/Immunology
Argininosuccinic acid participates in the fourth step of the urea cycle, with being cleaved to arginine and fumaric acid by argininosuccinic acid lyase (ASL). Argininosuccinic acid reduces reduced glutathione (GSH) level, and increases the production of reactive oxygen species in cerebral cortex and striatum. Argininosuccinic acid causes lipid peroxidation and protein oxidation, and induces oxidative stress in the developing rat brain .

HY-18138

PF-03382792	5-HT Receptor	Neurological Disease
PF-03382792 is a potent 5-HT₄ partial agonist with a K_i of 2.7 nM and an EC₅₀ of 0.9 nM for 5-HT_4d. PF-03382792 can penetrate the brain. PF-03382792 produces moderate increases in cortical Ach in the rat prefrontal cortex .

HY-101075

L-690330	Phosphatase	Others
L-690330 is a competitive inhibitor of inositol monophosphatase (IMPase) with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 exhibits 10-fold more sensitive than mouse and rat IMPase .

HY-101075A

L-690330 hydrate	Phosphatase	Others
L-690330 hydrate is a competitive inhibitor of inositol monophosphatase (IMPase) with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 hydrate exhibits 10-fold more sensitive than mouse and rat IMPase .

HY-103133

WAY208466 dihydrochloride	5-HT Receptor	Neurological Disease
WAY 208466 dihydrochloride is a potent and selective 5-HT₆ receptor agonist (EC₅₀=7.3 nM for the human 5-HT₆ receptor). WAY-208466 dihydrochloride elevates cortical GABA levels in rat frontal cortex . WAY 208466 dihydrochloride exhibits antidepressant and anxiolytic-like effects .

HY-113149A

Argininosuccinic acid disodium	Endogenous Metabolite Reactive Oxygen Species	Inflammation/Immunology
Argininosuccinic acid disodium participates in the fourth step of the urea cycle and is cleaved into arginine and fumarate by argininosuccinate lyase (ASL). Argininosuccinic acid disodium reduces reduced glutathione (GSH) concentrations and increases reactive oxygen species production in the cerebral cortex and striatum. Argininosuccinic acid disodium causes lipid peroxidation and protein oxidation and also induces oxidative stress in the developing rat brain .

HY-117839

PD-135666	Cholecystokinin Receptor	Neurological Disease
PD-135666 is a dipeptide inhibitor of cholecystokinin B (CCK B) receptors, binding to CCK B receptors in mouse cerebral cortex with IC50 of 0.1 nM. Its enantiomer, PD-140548, preferentially binds to CCK A receptors with IC50 of 2.8 nM in rat pancreas. PD-135666 exhibits anxiolytic effects in animal models .

HY-170409

BNN27	Trk Receptor Apoptosis	Neurological Disease Inflammation/Immunology
BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .

HY-114753

Neboglamine CR-2249; XY-2401	iGluR	Neurological Disease
Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .

HY-11051

JNJ-20788560	Opioid Receptor	Inflammation/Immunology
JNJ-20788560 is a selective and orally active delta opioid receptor agonist with an affinity of 2.0 nM for DOR (rat brain cortex binding assay). JNJ-20788560 also is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. JNJ-20788560 can be used for the research of the relief of inflammatory hyperalgesia .

HY-18730

1400W W1400	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-W795507

Cyanopindolol	Adrenergic Receptor 5-HT Receptor	Neurological Disease
Cyanopindolol is an β3-adrenoceptor antagonist. Cyanopindolol is a potent and selective antagonist at the presynaptic serotonin autoreceptor in the rat brain cortex. Cyanopindolol has binding affinity for 5-HT1A and 5-HT1B receptor (K_i: 2.1 and 3 nM respectively) .

HY-116062

JNJ-7925476 hydrochloride	Monoamine Transporter Dopamine Transporter Adrenergic Receptor	Others
JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.

HY-105115

Abecarnil ZK 112119	GABA Receptor	Neurological Disease
Abecarnil (ZK 112119) is a ligand or a partial agonist for benzodiazepine (BZ) receptor. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil can act as a positive allosteric modulator of GABA_A receptor. Abecarnil inhibits the binding of the BZ [3H]lormetazepam to rat cerebral cortex membranes, with an IC₅₀ of 0.82 nM. Abecarnil can be used for epilepsy research .

HY-111066

JNJ-37822681	Dopamine Receptor	Others
JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.

HY-10711A

ALX-5407 hydrochloride (R)-NFPS hydrochloride	GlyT	Neurological Disease
ALX-5407 ((R)-NFPS) hydrochloride is a selective and orally active glycine transporter GlyT1 inhibitor with an IC₅₀ value of 3 nM. ALX-5407 hydrochloride can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .

HY-168859

JNK3 inhibitor-9	JNK GSK-3 Amyloid-β	Neurological Disease
JNK3 inhibitor-9 (Compound 24a) is a potent, selective and BBB-permeable JNK3 inhibitor with an IC₅₀ value of 12 nM. JNK3 inhibitor-9 also potently inhibits GSK3α/β (IC₅₀s: 14 and 35 nM, respectively) involved in Tau phosphorylation. JNK3 inhibitor-9 reduces c-Jun and APP phosphorylation. JNK3 inhibitor-9 protects neurons from Aβ_1-42 toxicity .

HY-17550

Sunifiram DM-235	iGluR	Neurological Disease
Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-P3883

[DAla4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[DAla4] Substance P (4-11) is an analog of Substance P (Substance P (HY-P0201)) that inhibits the binding of ¹²⁵I-Bolton Hunter-conjugated Eledoisin (Eledoisin (HY-P0006)) (IC₅₀ of 0.5 μM) and ¹²⁵I-Bolton Hunter-conjugated Substance P (IC₅₀ of 0.15 μM) to rat brain cortex membranes .

HY-18731

1400W Dihydrochloride 15+ Cited Publications	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18730). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-59201A

A-582941 dihydrochloride	nAChR 5-HT Receptor	Neurological Disease
A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with K_is of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT₃ receptor with a K_i of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research .

HY-19651B

Zanapezil fumarate TAK-147 fumarate	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) fumarate is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil fumarate shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil fumarate shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil fumarate can be used for the research of early stages of Alzheimer's disease (AD) .

HY-19651A

Zanapezil TAK-147	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil can be used for the research of early stages of Alzheimer's disease (AD) .

HY-106874

Delequamine RS-15385-197	Adrenergic Receptor	Neurological Disease
Delequamine (RS-15385-197) is an orally active and selective α2-adrenergic receptor antagonist with a pK_i of 9.5 for α2-adrenoceptors in rat cortex. Delequamine shows >1000 fold selectivity against 5-HT1A receptors and α1-adrenoceptors. Delequamine can be used for the study of erectile dysfunction .

HY-106874A

Delequamine hydrochloride RS-15385-197 hydrochloride	Adrenergic Receptor	Neurological Disease
Delequamine (RS-15385-197) hydrochloride is an orally active and selective α2-adrenergic receptor antagonist with a pK_i of 9.5 for α2-adrenoceptors in rat cortex. Delequamine hydrochloride shows >1000 fold selectivity against 5-HT1A receptors and α1-adrenoceptors. Delequamine hydrochloride can be used for the study of erectile dysfunction .

HY-129245

Razobazam Hoe 175	Endogenous Metabolite	Neurological Disease
Razobazam (Hoe 175) is a benzodiazepine derivative with cognitive activity. Razobazam has been shown to improve learning performance in socially deprived rats. Razobazam increased avoidance scores by 18% after training. Razobazam caused significant changes in the optical density of certain areas of the rat brain, including a 22% decrease in the lateral habenula and a 25% increase in the ventral tegmental area. Razobazam also caused a 13% increase in optical density in the prefrontal cortex of rats .

HY-19651

Zanapezil free base TAK-147 free base	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) free base is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil free base shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil free base shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil free base can be used for the research of early stages of Alzheimer's disease (AD) .

HY-17550R

Sunifiram (Standard)	iGluR	Neurological Disease
Sunifiram (Standard) is the analytical standard of Sunifiram. This product is intended for research and analytical applications. Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-101046

Azaperone dimaleate Quipazine dimaleate	5-HT Receptor SARS-CoV	Neurological Disease
Quipazine dimaleate is a 5-HT agonist with a K_i value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine dimaleate shows antiviral activity against SARS-CoV-2 with an EC₅₀ of 31.64 μM. Quipazine dimaleate behaves as a 5-HT3R antagonist in peripheral models. Quipazine dimaleate can be used for neurological disease research .

HY-W028142

Quipazine	5-HT Receptor SARS-CoV	Neurological Disease
Quipazine is a 5-HT agonist with a K_i value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine shows antiviral activity against SARS-CoV-2 with an EC₅₀ of 31.64 μM. Quipazine behaves as a 5-HT3R agonist in peripheral models. Quipazine can be used for neurological disease research .

HY-116062A

JNJ-7925476	Histone Methyltransferase	Neurological Disease
JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Others Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

HY-135115

Oleuropein Aglycone 3,4-DHPEA-EA	α-synuclein HDAC Adrenergic Receptor	Inflammation/Immunology
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.

Cat. No.	Product Name	Type